Multilayer PVA adsorption onto hydrophobic drug substrates to engineer drug-rich microparticles.
Despite the availability of numerous crystal engineering techniques, generating drug-rich microparticles with a predetermined size, morphology and crystallinity still represents a significant challenge. A microparticle manufacturing method has recently been developed that attempts to 'shield' the physicochemical properties of micronised drugs by the application of a microfine polymer coating. The aims of this study were to investigate the nature of the drug-polymer interactions and determine the effects of this manufacturing strategy upon release of the drug from the microparticles. The adsorption of poly(vinyl alcohol) (PVA) on the micronised hydrophobic drug surface was found to reach equilibrium between 23 and 27 h. The Freundlich isotherm model was shown to give the most accurate fit to the experimental data and thus multilayer adsorption was assumed. The adsorptive capacity (1/n) was specific to the substrate and PVA grade. An increase in the PVA (%) hydrolysis value caused 1/n to increase from 0.76 to 1.05 using budesonide and from 0.31 to 0.79 when betamethasone valerate (BMV) was used. Increasing the molecular weight of the adsorbing polymer caused a reduction in the strength of PVA-adsorbate interaction when budesonide was used as the substrate (from 0.76 to 0.59), whereas a three-fold increase (from 0.31 to 0.86) was achieved when the BMV substrate was employed. A proportion of the adsorbed polymer was shown to remain associated with the substrate during the spray-drying process and the polymer coating resulted in a significantly higher (p<0.05, ANOVA) amount of drug release in 60 min (ca. 100%) compared to budesonide alone.
Buttini
F
F
Department of Pharmacy, University of Parma, Area delle Scienze, 43100 Parma, Italy.
Soltani
A
A
Colombo
P
P
Marriott
C
C
Jones
S A
SA
D000305:Adrenal Cortex Hormones / Q000737:chemistry / Q000493:pharmacokinetics; D000327:Adsorption; D000465:Algorithms; D001624:Betamethasone Valerate / Q000737:chemistry / Q000493:pharmacokinetics; D019819:Budesonide / Q000737:chemistry / Q000493:pharmacokinetics; D002138:Calibration; D003124:Colorimetry / Q000379:methods; D005612:Freeze Drying / Q000379:methods; D006868:Hydrolysis; D057927:Hydrophobic and Hydrophilic Interactions; D007700:Kinetics; D008863:Microspheres; D008970:Molecular Weight; D010316:Particle Size; D004364:Pharmaceutical Preparations / Q000737:chemistry* / Q000378:metabolism; D011108:Polymers / Q000737:chemistry; D011142:Polyvinyl Alcohol / Q000737:chemistry*; D012995:Solubility; D013678:Technology, Pharmaceutical / Q000379:methods; D013816:Thermodynamics
D000305:Adrenal Cortex Hormones; D004364:Pharmaceutical Preparations; D011108:Polymers; D019819:Budesonide; D011142:Polyvinyl Alcohol; D001624:Betamethasone Valerate